<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082832</url>
  </required_header>
  <id_info>
    <org_study_id>CMD-2019-001</org_study_id>
    <nct_id>NCT04082832</nct_id>
  </id_info>
  <brief_title>CuATSM Compared With Placebo for Treatment of ALS/MND</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collaborative Medicinal Development Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collaborative Medicinal Development Pty Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and
      efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or
      placebo for 6 x 28-day cycles (24 weeks) of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized 1:1 to CuATSM or placebo for 6 x 28-day cycles (24 weeks) of
      treatment. Study drug is administered orally, once a day in fasted state (before breakfast).
      Assessments for safety (physical examination, vital signs, hematology, serum chemistry
      adverse events) will be conducted at baseline and following each cycle of treatment.
      Assessments for efficacy (Revised ALS Functional Rating Scale [ASLFRS-R] score, and Edinburgh
      Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen [ECAS] score, and seated slow
      vital capacity [SVC]) will be conducted at baseline and following 2, 4 and 6 cycles of
      treatment. Analysis of covariance (ANCOVA) will be used to compare efficacy endpoints between
      CuATSM and placebo groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>ANCOVA will be used to compare efficacy endpoints between CuATSM and placebo groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Revised ALS Functional Rating Scale (ALSFRS-R) total score (range: 48 [best] to 0 [worst])</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessment of disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS) total score (range: 136 [best] to 0 [worst])</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessment of cognitive function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seated slow vital capacity (SVC)</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessment of respiratory function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>tolerability assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cu(II)ATSM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Powder for Oral Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cu(II)ATSM</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>Cu(II)ATSM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>Placebo Powder for Oral Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  familial or sporadic ALS/MNS by Awaji-shima Consensus Recommendations

          -  not taking riluzole or on stable dose of riluzole for 4 weeks prior to screening visit

          -  no prior exposure to agents other than riluzole for treatment of ALS

          -  adequate bone marrow reserve, renal and liver function

          -  women of childbearing potential must have a negative pregnancy test and be
             non-lactating

          -  women and men with partners of childbearing potential must take effective
             contraception while on treatment

        Exclusion Criteria:

          -  presence of a gastrointestinal disorder (eg, malabsorption) that might jeopardize
             intestinal absorption of study drug

          -  inability to perform seated SVC

          -  known immune compromising illness or treatment

          -  drug abuse or alcoholism

          -  clinically significant or active cardiovascular disease

          -  acute or chronic infection

          -  diagnosis of malignancy within 2 years prior to screening

          -  dementia that may affect patient understanding and/or compliance with study
             requirements and procedures

          -  current use of strong inducers or inhibitors of CYPs 2C19 and 2D6

          -  current us of medications (other than riluzole) that are metabolized predominantly by
             CYP 1A2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic Rowe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Macquarie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kay Noel, PhD</last_name>
    <phone>(415) 444 9600</phone>
    <email>Kay.Noel@colMedDev.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Rosenfeld, MD</last_name>
    <phone>(415) 444 9600</phone>
    <email>CraigR@ColMedDev.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Rowe, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

